<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To investigate the potential of <z:chebi fb="3" ids="44915">propofol</z:chebi> in suppressing <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> and to examine whether <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> ATP-sensitive <z:chebi fb="120" ids="26216">potassium</z:chebi> channels are involved </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Male Sprague-Dawley rats were pretreated with intravenous infusion of <z:chebi fb="3" ids="44915">propofol</z:chebi> (Prop), a selective <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> KATP channel inhibitor 5-hydroxydecanoate (5-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>), <z:chebi fb="3" ids="44915">propofol</z:chebi> plus 5-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> (Prop+5-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>), a potent <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> K(ATP) channel opener <z:chebi fb="0" ids="4495">diazoxide</z:chebi> (DZ) or NS, respectively </plain></SENT>
<SENT sid="2" pm="."><plain>The dosage of each drug was 10 mg/kg </plain></SENT>
<SENT sid="3" pm="."><plain>The animals then underwent a 30 min-ligation of the left anterior descending artery </plain></SENT>
<SENT sid="4" pm="."><plain>The severity of <z:hpo ids='HP_0011675'>arrhythmias</z:hpo>, the incidence of <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>), and the time of the first run of <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> were documented using an <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> scoring system </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0001427'>Mitochondrial</z:hpo> membrane potential (ΔΨm) was measured in freshly isolated rat cardiomyocytes with a fluorescence microscope </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: The <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> scores in the Prop and DZ group were 2.6(0-5) and 2.4(0-5), respectively, which were significantly lower than that in the control group [4.9(2-8)] </plain></SENT>
<SENT sid="7" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> was not observed in both Prop and DZ groups </plain></SENT>
<SENT sid="8" pm="."><plain>The first run of <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> was significantly postponed in the Prop group (10.5±2.2 vs 7.3±1.9 min) </plain></SENT>
<SENT sid="9" pm="."><plain>Bracketing of <z:chebi fb="3" ids="44915">propofol</z:chebi> with 5-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> eliminated the anti-arrhythmic effect of <z:chebi fb="3" ids="44915">propofol</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>In isolated rat cardiomyocytes, <z:chebi fb="3" ids="44915">propofol</z:chebi> (50 μmol/L) significantly decreased ΔΨm, but when <z:chebi fb="3" ids="44915">propofol</z:chebi> was co-administered with 5-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>, the effect on ΔΨm was reversed </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: <z:chebi fb="3" ids="44915">Propofol</z:chebi> preconditioning suppresses <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> in the rat heart, which are proposed to be caused by opening of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> K(ATP) channels </plain></SENT>
</text></document>